Genelux (GNLX) and Newsoara BioPharma said Tuesday that preliminary data from their co-sponsored ongoing phase 1b/2 small-cell lung cancer study indicated anti-tumor effect from Olvi-Vec immunochemotherapy.

In the initial dose escalation groups, five of the seven evaluable participants for anti-tumor response achieved disease control as the best response, with two of those five exhibiting a partial response, the companies said.

Those five also showed reductions in all of their individual target lesions, according to the companies.

The companies added that Olvi-Vec was "generally well-tolerated with a favorable safety profile."

They said enrollment into dose escalation groups continues to evaluate safety and the recommended intravenous dose for the phase 2 trial of Olvi-Vec, which they said is Genelux's most advanced product candidate.

Price: 3.46, Change: -0.43, Percent Change: -11.05